ISONIAZID tablet

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

ISONIAZID (UNII: V83O1VOZ8L) (ISONIAZID - UNII:V83O1VOZ8L)

Available from:

Mikart, LLC

INN (International Name):

ISONIAZID

Composition:

ISONIAZID 100 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parentheses): Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have > 10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the

Product summary:

Isoniazid Tablets, USP are available as follows: 100 mg Tablets: white, round, scored on one side. Available in bottles of 100 300 mg Tablets: white, round, scored on one side. Available in bottles of 30, 100 and 1000. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from moisture and light.

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

ISONIAZID- ISONIAZID TABLET
MIKART, LLC
----------
WARNING
Severe and sometimes fatal hepatitis associated with isoniazid therapy
has been reported and may
occur or may develop even after many months of treatment. The risk of
developing hepatitis is age
related. Approximate case rates by age are: less than 1 per 1,000 for
persons under 20 years of
age, 3 per 1,000 for persons in the 20 to 34 year age group, 12 per
1,000 for persons in the 35 to
49 year age group, 23 per 1,000 for persons in the 50 to 64 year age
group and 8 per 1,000 for
persons over 65 years of age. The risk of hepatitis is increased with
daily consumption of
alcohol. Precise data to provide a fatality rate for isoniazid-related
hepatitis is not available;
however, in a U.S. Public Health Service Surveillance Study of 13,838
persons taking isoniazid,
there were 8 deaths among 174 cases of hepatitis.
Therefore, patients given isoniazid should be carefully monitored and
interviewed at monthly
intervals. For persons 35 and older, in addition to monthly symptom
reviews, hepatic enzymes
(specifically, AST and ALT (formerly SGOT and SGPT, respectively))
should be measured prior
to starting isoniazid therapy and periodically throughout treatment.
Isoniazid-associated hepatitis
usually occurs during the first three months of treatment. Usually,
enzyme levels return to normal
despite continuance of drug, but in some cases progressive liver
dysfunction occurs. Other
factors associated with an increased risk of hepatitis include daily
use of alcohol, chronic liver
disease and injection drug use. A recent report suggests an increased
risk of fatal hepatitis
associated with isoniazid among women, particularly black and Hispanic
women. The risk may
also be increased during the post-partum period. More careful
monitoring should be considered
in these groups, possibly including more frequent laboratory
monitoring. If abnormalities of liver
function exceed three to five times the upper limit of normal,
discontinuation of isoniazid should
be strongly considered.